welcome
About us
Newsletter
News Widget
Media Inquiries

Summary

MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals

This is a news story, published by Yahoo Finance, that relates primarily to MIRA Pharmaceuticals, Inc. news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

SKNY Pharmaceuticals

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest MIRA Pharmaceuticals news, growth pharmaceutical markets news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

SKNY shareholders
Benzinga

Benzinga

•

Health

Health

MIRA Pharmaceuticals signs binding letter of intent to acquire SKNY Pharmaceuticals

Benzinga
Summary
Nutrition label

70% Informative

MIRA Pharmaceuticals, Inc. signed a binding letter of intent ( LOI ) to acquire SKNY Pharmaceuticals .

SKNY-1 is a preclinical-stage oral drug candidate for weight loss and smoking cessation.

MIRA stock is trading lower by 3.12% to $ 1.24 premarket at the last check.

VR Score

61

Informative language

58

Neutral language

63

Article tone

formal

Language

English

Language complexity

72

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

6

https://www.benzinga.com/general/biotech/25/03/44299076/exclusive-mira-pharmaceuticals-expands-pipeline-enhances-value-proposition-with-development-of-topical-formulation-for-lead-pain-treatment-candidate?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=44454746https://www.benzinga.com/general/health-care/25/03/44454746/exclusive-mira-pharmaceuticals-signs-to-acquire-skny-pharmaceuticals-expand-pipeline-into-weihttps://www.benzinga.comhttps://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spja3yaad1&utm_source=yahoohttps://www.benzinga.com/25/03/44442111/accentures-stock-price-a-prime-entry-point-for-investors-says-goldman-sachs-analyst?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=44454746https://www.benzinga.com/general/biotech/25/03/44105645/exclusive-mira-pharmaceuticals-kick-starts-human-trial-in-israel-for-ketamir-2-for-neuropathic-pain?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=44454746

Source diversity

1

www.benzinga.com

Affiliate links

no affiliate links

Read full article

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.

Powered by Otherweb